PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8732432-1 1996 Our objective was to study the re-expression of CD4 and CD8 on activated human T-lymphocytes in the presence of dexamethasone and cyclosporine A at physiologically relevant concentrations. Cyclosporine 130-144 CD8a molecule Homo sapiens 56-59 8704690-4 1996 Cyclosporine was used as GVHD prophylaxis in combination with CD4+ and CD8+ depletion, which removed 94.1 +/- 3.2%, 97.0 +/- 5.1%, and 96.7 +/- 3.1% of CD3+, CD4+ and CD8+ cells, respectively. Cyclosporine 0-12 CD8a molecule Homo sapiens 167-170 8598229-0 1996 Strong increase in the percentage of the CD8bright+ CD28- T-cells and delayed engraftment associated with cyclosporine-induced autologous GVHD. Cyclosporine 106-118 CD8a molecule Homo sapiens 41-44 8732432-9 1996 We concluded that activation of T-lymphocytes results in rapid down-modulation of surface CD3, CD4 and CD8 followed by re-expression which is inhibited in the case of CD4, but not CD8, by dexamethasone and cyclosporine A. Cyclosporine 206-220 CD8a molecule Homo sapiens 103-106 9026809-3 1996 Administration of CsA-treated lymphocytes induced no profound structural changes in lymphocytic subpopulations (CD3, CD4, CD8), but it was followed by a reduction in the baseline high proliferative lymphocytic response to PHA. Cyclosporine 18-21 CD8a molecule Homo sapiens 122-125 9700361-1 1995 Cyclosporin A (CsA) inhibits the development of mature thymocytes from their CD4+ CD8+ precursors, but may allow autoreactive cells to mature. Cyclosporine 0-13 CD8a molecule Homo sapiens 82-85 7541577-0 1995 Implication of cyclosporine in up-regulation of Bcl-2 expression and maintenance of CD8 lymphocytosis in cytomegalovirus-infected allograft recipients. Cyclosporine 15-27 CD8a molecule Homo sapiens 84-87 7541577-11 1995 Combination of CMV latent infection and cyclosporine therapy appears therefore critical to shift the homeostatic maintenance of the peripheral lymphocyte compartment toward persistingly high numbers of CD8+ T cells. Cyclosporine 40-52 CD8a molecule Homo sapiens 202-205 7586731-0 1995 Direct inhibition of human CD8+ lymphocyte activation by cyclosporine A and Rapamune-Sirolimus. Cyclosporine 57-71 CD8a molecule Homo sapiens 27-30 7586731-2 1995 In this study the direct effects of RAP and CsA on a highly purified population of CD8+ lymphocytes were examined. Cyclosporine 44-47 CD8a molecule Homo sapiens 83-86 9700361-1 1995 Cyclosporin A (CsA) inhibits the development of mature thymocytes from their CD4+ CD8+ precursors, but may allow autoreactive cells to mature. Cyclosporine 15-18 CD8a molecule Homo sapiens 82-85 9700361-5 1995 An exceptional subset of CD8 SP thymocytes, expressing CD45RA, did not respond to CsA for about 10 days, indicating that they are distantly derived from a CsA-sensitive precursor. Cyclosporine 155-158 CD8a molecule Homo sapiens 25-28 9700361-6 1995 Apoptosis of TCR-V beta 3 + thymocytes caused by Mtv-6, quantified according to the down-regulation of CD4 and CD8 on immature thymocytes, was partially inhibited by CsA, to maximal effect within 24 hours. Cyclosporine 166-169 CD8a molecule Homo sapiens 111-114 8137549-6 1994 Cyclosporine inhibited IL-2 receptor expression to a significantly greater degree in cord CD4 and CD8 cells (49.7% and 70.1%) than in adults (17.9% and 30.0%). Cyclosporine 0-12 CD8a molecule Homo sapiens 98-101 8082307-6 1994 A statistically significant correlation was calculated between the levels of soluble CD8 and whole blood cyclosporin A level. Cyclosporine 105-118 CD8a molecule Homo sapiens 85-88 8184875-5 1994 Following in vivo treatment with cyclosporin peripheral blood CD4/CD8 ratios returned to normal. Cyclosporine 33-44 CD8a molecule Homo sapiens 66-69 8500270-0 1993 In vivo and in vitro suppression of T-cell receptor alpha/beta CD4- CD8- T lymphocytes by cyclosporine A. Cyclosporine 90-104 CD8a molecule Homo sapiens 68-71 7608852-8 1994 Likewise, the intraepithelial deposit of CsA in the GO region was found to be related to the inflammatory infiltrate CD4+, CD8+, and CD68+ (r = 0.7432; r = 0.7346; r = 0.77005, respectively). Cyclosporine 41-44 CD8a molecule Homo sapiens 123-126 7684344-12 1993 Cyclosporin use was associated with a significant decrease in CD45RA antigen density on both CD4+ and CD8+ T-cells. Cyclosporine 0-11 CD8a molecule Homo sapiens 102-105 8500270-6 1993 CsA also inhibited the cytolytic activity and cytokine production of in vitro cultured TCR alpha/beta+ CD4- CD8- cell lines. Cyclosporine 0-3 CD8a molecule Homo sapiens 108-111 8500270-7 1993 Our data suggest that alleviation of the patient"s clinical symptoms resulted from cyclosporine-mediated suppression of proliferation, cytotoxicity, and inflammatory cytokine production of TCR alpha/beta+ CD4- CD8- T lymphocytes in vivo. Cyclosporine 83-95 CD8a molecule Homo sapiens 210-213 1906396-1 1991 A study was made of changes in the ratio of CD4+/CD8+ in patients who had received cadaverous kidneys and who were under treatment with a combination of cyclosporin A + azathioprine + cor ticosteroids. Cyclosporine 153-166 CD8a molecule Homo sapiens 49-52 8438399-0 1993 Cyclosporine preferentially inhibits clonal deletion of CD8-positive T cells with an MHC class II restricted autoreactive T-cell receptor. Cyclosporine 0-12 CD8a molecule Homo sapiens 56-59 7511004-11 1993 Flow cytometric analysis of peripheral blood cells prior to treatment with Cyclosporin-A showed systemic activation of lymphocytes, with high levels of HLA-DR and CD25 expression and a raised CD4/CD8 ratio. Cyclosporine 75-88 CD8a molecule Homo sapiens 196-199 1497650-0 1992 Correlation between up-regulation of lymphokine mRNA and down-regulation of TcR, CD4, CD8 and lck mRNA as shown by the effect of CsA on activated T lymphocytes. Cyclosporine 129-132 CD8a molecule Homo sapiens 86-89 1432999-0 1992 Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis. Cyclosporine 0-12 CD8a molecule Homo sapiens 105-108 1898996-4 1991 Administration of CsA following syngeneic bone marrow transplantation leads to a developmental arrest of mature CD4+ and CD8+ T lymphocytes in the thymus and a marked reduction in cells expressing the alpha beta T cell receptor. Cyclosporine 18-21 CD8a molecule Homo sapiens 121-124 1968392-6 1990 Similarly, pretreatment of a CD8 clone with actinomycin D or CsA inhibited lymphokine production without affecting cytolytic activity. Cyclosporine 61-64 CD8a molecule Homo sapiens 29-32 1971791-2 1990 CsA specifically inhibited the generation of cells expressing high levels of alpha/beta TcR/CD3 complexes and a mature phenotype defined by CD4 and CD8 surface markers. Cyclosporine 0-3 CD8a molecule Homo sapiens 148-151 2141324-3 1990 Purified CD8+ responder cells were inhibited as effectively by CsA as unfractionated cells, suggesting that CsA has a direct, lymphokine-independent effect on CD8+ cells. Cyclosporine 63-66 CD8a molecule Homo sapiens 9-12 2141324-3 1990 Purified CD8+ responder cells were inhibited as effectively by CsA as unfractionated cells, suggesting that CsA has a direct, lymphokine-independent effect on CD8+ cells. Cyclosporine 108-111 CD8a molecule Homo sapiens 9-12 2141324-3 1990 Purified CD8+ responder cells were inhibited as effectively by CsA as unfractionated cells, suggesting that CsA has a direct, lymphokine-independent effect on CD8+ cells. Cyclosporine 108-111 CD8a molecule Homo sapiens 159-162 35369435-9 2022 Interestingly, when we blunted antiviral immune responses using clodronate liposomes (which depletes antigen-presenting cells) or cyclosporin (which inhibits cytokine production that regulates T-cell proliferation), significantly lower IFN-gamma producing CD8+ T cells infiltrated into tendon tissues, resulting in reduced tendon tissues apoptosis and milder disease manifestations. Cyclosporine 130-141 CD8a molecule Homo sapiens 256-259 35553638-10 2022 Cyclosporine A and prednisolone synergistically increased GCR expression and inhibited pro-inflammatory cytokine production by CD28null CD8- T and NKT-like cells. Cyclosporine 0-14 CD8a molecule Homo sapiens 136-139 2526799-5 1989 Furthermore, proliferation of CD8+CD11- cells, considered a cytotoxic T cell subset, were inhibited significantly more in anti-IL2 RAb-treated MLR culture than in CsA-treated MLR culture. Cyclosporine 163-166 CD8a molecule Homo sapiens 30-33 2809194-4 1989 Addition of CsA to organ culture resulted in a decreased cell yield and complete inhibition of the appearance of TCR-alpha beta-bearing, single positive thymocytes (both CD4+CD8- and CD4-CD8+). Cyclosporine 12-15 CD8a molecule Homo sapiens 174-177 2809194-4 1989 Addition of CsA to organ culture resulted in a decreased cell yield and complete inhibition of the appearance of TCR-alpha beta-bearing, single positive thymocytes (both CD4+CD8- and CD4-CD8+). Cyclosporine 12-15 CD8a molecule Homo sapiens 187-190 2809194-5 1989 Furthermore, the generation of CD4+CD8+ thymocytes was markedly inhibited by CsA treatment, whereas the development of CD3-, CD4-CD8+ thymocytes and TCR-gamma delta-bearing, CD4-CD8- thymocytes was not affected. Cyclosporine 77-80 CD8a molecule Homo sapiens 35-38 33317956-9 2021 Treatment with prednisolone + theophylline + cyclosporin A inhibited IFN-gamma and TNF-alpha production by SA CD28null CD8+ T and NKT-like cells additively. Cyclosporine 45-58 CD8a molecule Homo sapiens 119-122 2784322-4 1989 In the epidermis of the cyclosporin-injected plaques, total and HLA-DR+ CD4+ and CD8+ T cell numbers were significantly decreased compared to corresponding plaques treated with placebo (total CD4+, total CD8+, DR+ CD4+, P less than 0.01; DR+ CD8+, P less than 0.02). Cyclosporine 24-35 CD8a molecule Homo sapiens 81-84 2784322-4 1989 In the epidermis of the cyclosporin-injected plaques, total and HLA-DR+ CD4+ and CD8+ T cell numbers were significantly decreased compared to corresponding plaques treated with placebo (total CD4+, total CD8+, DR+ CD4+, P less than 0.01; DR+ CD8+, P less than 0.02). Cyclosporine 24-35 CD8a molecule Homo sapiens 204-207 2784322-4 1989 In the epidermis of the cyclosporin-injected plaques, total and HLA-DR+ CD4+ and CD8+ T cell numbers were significantly decreased compared to corresponding plaques treated with placebo (total CD4+, total CD8+, DR+ CD4+, P less than 0.01; DR+ CD8+, P less than 0.02). Cyclosporine 24-35 CD8a molecule Homo sapiens 204-207 2784322-5 1989 Similarly, T lymphocyte numbers in the dermis were decreased in the cyclosporin compared to placebo-treated plaques; the reduction in total CD4+ and DR+ CD8+ T cell numbers was statistically significant (P less than 0.05). Cyclosporine 68-79 CD8a molecule Homo sapiens 153-156 3314787-6 1987 In acquired immunodeficiency syndrome, graft-vs-host disease, and cyclosporine therapy, there is an expansion of cytotoxic/suppressor (CD8) lymphocytes. Cyclosporine 66-78 CD8a molecule Homo sapiens 135-138 28102966-9 2017 Treatment with 10 mg/L theophylline + 1 micromol/L prednisolone or 2.5 ng/mL cyclosporine A synergistically upregulated HDAC2 and inhibited IFN-gamma and TNF-alpha production by CD8+ T and NKT-like lymphocytes. Cyclosporine 77-91 CD8a molecule Homo sapiens 178-181 29352737-7 2018 The addition of 2 5 ng/ml cyclosporin A and 1 microM prednisolone inhibit IFN-gamma/TNF-alpha production significantly by CD8+ Pgp+ T cells from BOS patients. Cyclosporine 26-39 CD8a molecule Homo sapiens 122-125 29746028-19 2017 After CsA treatment, CD3 level in maternal blood was higher in successful group than abortion group but CD8 level was decreased after CsA treatment. Cyclosporine 6-9 CD8a molecule Homo sapiens 104-107 29746028-19 2017 After CsA treatment, CD3 level in maternal blood was higher in successful group than abortion group but CD8 level was decreased after CsA treatment. Cyclosporine 134-137 CD8a molecule Homo sapiens 104-107 26921303-5 2016 The aim of this study was to evaluate the influence of the immunosuppressive drugs cyclosporine A (CsA) and rapamycin (RAPA) on the level, suppressor properties, and phenotype of human CD8(+)CD28(-) T cells in vitro. Cyclosporine 83-97 CD8a molecule Homo sapiens 185-188 27101736-5 2016 CsA treatment significantly decreased the percentages of CD4+ and CD8+ T lymphocytes in the thymus (P<0.01). Cyclosporine 0-3 CD8a molecule Homo sapiens 66-69 27101736-7 2016 CsA treatment significantly depleted the peripheral blood CD3+, CD4+ and CD8+ T lymphocytes (P<0.01). Cyclosporine 0-3 CD8a molecule Homo sapiens 73-76 26921303-5 2016 The aim of this study was to evaluate the influence of the immunosuppressive drugs cyclosporine A (CsA) and rapamycin (RAPA) on the level, suppressor properties, and phenotype of human CD8(+)CD28(-) T cells in vitro. Cyclosporine 99-102 CD8a molecule Homo sapiens 185-188 26921303-7 2016 It was observed that CD8(+)CD28(-) T cells from cultures with CsA or RAPA had similar suppressor properties to cells from control cultures, although the drugs influenced the expression of FOXP3. Cyclosporine 62-65 CD8a molecule Homo sapiens 21-24 22538855-6 2012 Critically, CD8(+)FoxP3(+) T(reg) are exquisitely sensitive to inhibition by cyclosporine but can be massively and specifically expanded in vivo to prevent GVHD by coadministering rapamycin and IL-2 antibody complexes. Cyclosporine 77-89 CD8a molecule Homo sapiens 12-15 25238936-1 2014 A 55-year-old female with T-cell large granular lymphocytic leukemia (T-LGL) (CD8+) was initially treated with anti-thymocyte globulin and then cyclosporine due to anemia/neutropenia. Cyclosporine 144-156 CD8a molecule Homo sapiens 78-81 22484354-6 2012 Analysis of T-cell phenotype by flow cytometry in 2 subjects showed a decrease in circulating activated CD8(+) and CD4(+) T effector memory cells after treatment with CSA. Cyclosporine 167-170 CD8a molecule Homo sapiens 104-107 23936793-3 2013 Flow cytometry showed that the number of CD4(+) and CD8(+) cells and the level of IFN- gamma decreased significantly in the groups treated with cyclosporin A. Cyclosporine 144-157 CD8a molecule Homo sapiens 52-55 22329558-0 2012 Expansion of CD8+/perforin+ T-cells predicts response to ciclosporin A therapy in patients with erythroid hypoplasia/aplasia. Cyclosporine 57-70 CD8a molecule Homo sapiens 13-16 21401729-3 2011 Tacr- compared with CsA-based immunosuppression was independently associated with increased IL-2 (P<0.0001, CD4 cells; P=0.014, CD8 cells) and CD4 cell IL-4 responses (P=0.046; stepwise logistic regression) resulting in physiological responses in Tacr/Aza patients as compared with 25 healthy controls. Cyclosporine 20-23 CD8a molecule Homo sapiens 131-134 22974789-11 2012 CONCLUSIONS: Our data indicate that small molecules immunosuppressants, especially CsA, inhibit Pgp activity and T-cell function being the CD8+ T cells more susceptible to this effect. Cyclosporine 83-86 CD8a molecule Homo sapiens 139-142 21343581-3 2011 Many younger patients who respond to immunosuppressive therapy with drugs such as antithymocyte globulin and cyclosporine have clonal expansions of cytotoxic CD8(+) T cells that suppress normal hematopoiesis, as well as expansion of CD4(+) helper T-cell subsets that promote and sustain autoimmunity. Cyclosporine 109-121 CD8a molecule Homo sapiens 158-161 20663037-8 2010 Both PSP and ciclosporin blocked the reduction of the CD4/CD8 ratio in stimulated lymphocytes. Cyclosporine 13-24 CD8a molecule Homo sapiens 58-61 20043941-5 2010 CsA-treatment resulted in a significant reduction of absolute numbers of circulating CD4(+) and CD8alpha(+) T-lymphocytes by up to 82 and 65%, respectively (P<0.05). Cyclosporine 0-3 CD8a molecule Homo sapiens 96-104 19233271-11 2009 On the other hand, in vitro assays showed that cyclosporine (5.0 ug/mL) and tacrolimus (100 ng/mL) diminished the percentages of CD8+CD28- cells, with no significant effect on natural T regulatory cells. Cyclosporine 47-59 CD8a molecule Homo sapiens 129-132 20406686-8 2010 Naive CD8(+) T-lymphocytes increased versus baseline in the cyclosporine cohort at months 1 and 3, but remained unchanged with sirolimus. Cyclosporine 60-72 CD8a molecule Homo sapiens 6-9 20406686-10 2010 The proportion of memory CD8(+) T-lymphocytes decreased at months 1 and 3 compared to baseline in the CsA arm, but did not change in the sirolimus cohort. Cyclosporine 102-105 CD8a molecule Homo sapiens 25-28 17490541-7 2007 After treatment with cyclosporine A, 9 out of 11 patients got good response, and CD3(+), CD8(+) cells in the responding patient decreased, the ratio of CD4(+)/CD8(+) returned to normal, and gammadelta T cells also decreased to normal range. Cyclosporine 21-35 CD8a molecule Homo sapiens 89-92 18845086-0 2008 [Regulatory function of tacrolimus and CsA on CD4/CD8 T lymphocyte subgroups and costimulators on them in allo-liver recipients]. Cyclosporine 39-42 CD8a molecule Homo sapiens 50-53 18845086-1 2008 AIM: To explore the regulatory function of FK506 and CsA on CD4/CD8 T lymphocyte subgroups and co-stimulators on them. Cyclosporine 53-56 CD8a molecule Homo sapiens 64-67 18845086-6 2008 Between two treatment group, the expression of CD4(+)T cells and the expression of CD28 and ICOS on CD8(+)T cells in CsA-treated group were much higher than those in FK506-treated group (P<0.05), and there was no significant difference between two treatment groups in other indexes. Cyclosporine 117-120 CD8a molecule Homo sapiens 100-103 19016371-9 2008 However, with 45/52 (86.5%) the tetramer technology was superior to the CSA, which detected 34/52 (65.4%) based on CD8(+) T cells and 41/52 (78.8%) based on both CD4(+) and CD8(+) T cells. Cyclosporine 72-75 CD8a molecule Homo sapiens 115-118 17490541-7 2007 After treatment with cyclosporine A, 9 out of 11 patients got good response, and CD3(+), CD8(+) cells in the responding patient decreased, the ratio of CD4(+)/CD8(+) returned to normal, and gammadelta T cells also decreased to normal range. Cyclosporine 21-35 CD8a molecule Homo sapiens 159-162 17042130-10 2006 Cyclosporine inhibits CD8 activation and thus may reduce epidermal destruction. Cyclosporine 0-12 CD8a molecule Homo sapiens 22-25 17056460-0 2006 Combined low dose cyclosporine and prednisone down-regulate natural killer cell-like effector functions of CD8brightCD56+ T cells in patients with active Behcet uveitis. Cyclosporine 18-30 CD8a molecule Homo sapiens 107-110 17056460-1 2006 PURPOSE: To investigate the changes of effector-related phenotypic markers and the natural killer (NK)-like effector functions of CD8(bright)CD56+ T cells in patients with Behcet uveitis after combined cyclosporine and prednisone (Cs/Pd) treatment. Cyclosporine 202-214 CD8a molecule Homo sapiens 130-133 15899924-2 2005 Immunosuppressive drugs, such as FK506 and cyclosporin A, block the priming of alloreactive CD4 T(h) cells and the subsequent induction of allospecific CD8 cytotoxic effector T cells and inhibit allograft rejection. Cyclosporine 43-56 CD8a molecule Homo sapiens 152-155 16116173-5 2005 However, we demonstrate that a brief course of cyclosporine A to rat renal allograft recipients promotes progressive accumulation of CD103+CD8+ cells within the graft, concomitant with the development of tubular atrophy and interstitial fibrosis. Cyclosporine 47-61 CD8a molecule Homo sapiens 139-142 16756642-3 2006 The aim of the present study was to evaluate P-gp expression on the surface of CD4(+), CD8(+), CD19(+) and CD56(+) cells in kidney transplant patients treated with cyclosporine A as a main immunosuppressant, using flow cytometry. Cyclosporine 164-178 CD8a molecule Homo sapiens 87-90 14550820-7 2003 RESULTS: CsA and FK 506 reduced the presence graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) in the PVS of intra- and epicardial arteries when compared with control animals. Cyclosporine 9-12 CD8a molecule Homo sapiens 81-84 14579273-6 2003 Cyclosporin A, but not concanamycin A, an H+-ATPase vacuolar inhibitor which affects perforin and granzyme release, strongly reduced the sHLA-I-mediated CD8-dependent IFN-gamma production but did not affect cytolytic activity of NK cells, suggesting that different biochemical pathways are involved. Cyclosporine 0-13 CD8a molecule Homo sapiens 153-156 14579273-7 2003 Altogether, these findings indicate that CD8 engagement by sHLA-I activates a cyclosporin A-dependent pathway leading to production and secretion of IFN-gamma which may play a role in the regulation of innate immune responses in humans. Cyclosporine 78-91 CD8a molecule Homo sapiens 41-44 15671024-4 2005 Treatment with cyclosporin A significantly reduced surface expression of CD147 and of CD8-CD147 fusion protein carrying the extracellular domain of CD8 fused to the transmembrane and cytoplasmic domains of CD147, but did not affect expression of CD8. Cyclosporine 15-28 CD8a molecule Homo sapiens 86-89 15671024-4 2005 Treatment with cyclosporin A significantly reduced surface expression of CD147 and of CD8-CD147 fusion protein carrying the extracellular domain of CD8 fused to the transmembrane and cytoplasmic domains of CD147, but did not affect expression of CD8. Cyclosporine 15-28 CD8a molecule Homo sapiens 148-151 15671024-4 2005 Treatment with cyclosporin A significantly reduced surface expression of CD147 and of CD8-CD147 fusion protein carrying the extracellular domain of CD8 fused to the transmembrane and cytoplasmic domains of CD147, but did not affect expression of CD8. Cyclosporine 15-28 CD8a molecule Homo sapiens 148-151 12421236-7 2002 CONCLUSIONS: The present observations, contrary to expectation, reveal that lower cell densities of CD4+ T cells and lower CD4/CD8 ratios are associated with responsiveness to CsA in combination therapy, suggesting that pharmacological actions other than suppression of CD4+ T cells explain the efficacy of CsA in patients with chronic IP. Cyclosporine 176-179 CD8a molecule Homo sapiens 127-130 12543899-10 2003 Immunophenotyping indicated expansion of CD8(+) and CD25(+) lymphocyte subsets following allo-stimulation that was inhibited by increasing concentrations of CsA. Cyclosporine 157-160 CD8a molecule Homo sapiens 41-44 12197897-7 2002 These results indicate that activated Th1-type pulmonary T cells play an important role in the development of corticosteroid- resistant IP in DM/PM and that the increase in CD25+ CD8+ T cells in BALF is a useful indicator for corticosteroid-resistant IP in DM/PM and hence may be an indicator for early use of cyclosporin. Cyclosporine 310-321 CD8a molecule Homo sapiens 179-182 12421236-5 2002 CD4/CD8 ratios of CsA responders were also significantly lower than those of non-responders (0.315 +/- 0.070 vs 1.975 +/- 0.965, P=0.0463). Cyclosporine 18-21 CD8a molecule Homo sapiens 4-7 12806026-18 2002 Interestingly, soluble Fas-ligand secretion and CD8+ cell apoptosis, but not CD8+ cell cytolitic activity, are completely inhibited by Cyclosporin A, which specifically blocks the activation of the calcineurin/calmodulin pathway. Cyclosporine 135-148 CD8a molecule Homo sapiens 48-51 11923685-8 2002 The CsA-treated mothers and their pups (15 and 25 mg/kg/day dose) had a significant increase in the percentage of CD4+CD8+ thymocytes and a significant decrease in the percentages of CD4+, CD3hi, and T-cell receptor (TCR)hi thymocyte phenotype subsets and CD4/CD8 ratios. Cyclosporine 4-7 CD8a molecule Homo sapiens 118-121 11923685-8 2002 The CsA-treated mothers and their pups (15 and 25 mg/kg/day dose) had a significant increase in the percentage of CD4+CD8+ thymocytes and a significant decrease in the percentages of CD4+, CD3hi, and T-cell receptor (TCR)hi thymocyte phenotype subsets and CD4/CD8 ratios. Cyclosporine 4-7 CD8a molecule Homo sapiens 260-263 11399937-7 2001 RESULTS: Significant reductions were observed with respect to the percentages of CD4+ and CD23+ cells in the conjunctival impression cytology specimens and clinical and symptom scores following treatment with topical CsA, while no change occurred in the percentages of CD8+ and CD45RA+ cells. Cyclosporine 217-220 CD8a molecule Homo sapiens 269-272 11813632-0 2001 [Quantitative changes in CD4+ and CD8+ T-lymphocytes in the skin of patients with psoriasis treated with cyclosporin A]. Cyclosporine 105-118 CD8a molecule Homo sapiens 34-37 11681844-12 2001 CD8(+) lymphocytes and microglia cells are most likely important effector cells in the late, cyclosporin A-resistant rejection process. Cyclosporine 93-106 CD8a molecule Homo sapiens 0-3 11750417-0 2001 CD4 and CD8 cytokine-producing T cells are transiently reduced following cyclosporine intake: maximal inhibition occurs at 2 hours coincidental with drug C(max). Cyclosporine 73-85 CD8a molecule Homo sapiens 8-11 11586066-9 2001 Ciclosporin, in contrast, was found to inhibit perforin-granule release significantly and dose dependently: whereas release from CD8(+) lymphocytes was almost maximal for the untreated control after 60 min (41% of CD8(+) perforin(+) cells at time zero), ciclosporin at 20, 4 and 2 microg/ml elevated the aforementioned parameter up to 73, 65 and 53%, respectively. Cyclosporine 0-11 CD8a molecule Homo sapiens 129-132 11586066-9 2001 Ciclosporin, in contrast, was found to inhibit perforin-granule release significantly and dose dependently: whereas release from CD8(+) lymphocytes was almost maximal for the untreated control after 60 min (41% of CD8(+) perforin(+) cells at time zero), ciclosporin at 20, 4 and 2 microg/ml elevated the aforementioned parameter up to 73, 65 and 53%, respectively. Cyclosporine 0-11 CD8a molecule Homo sapiens 214-217 10729997-5 2000 The absolute number of CD8+CD57+ cells in the patients with grade II-IV acute GVHD was also significantly higher in the tacrolimus group compared with the CsA group. Cyclosporine 155-158 CD8a molecule Homo sapiens 23-26 11074805-5 2000 RESULTS: In cyclosporine-treated eyes, biopsy results of conjunctivae showed decreases in the number of cells positive for CD3, CD4, and CD8, while in vehicle-treated eyes, results showed increases in these markers, although these differences were not statistically significant. Cyclosporine 12-24 CD8a molecule Homo sapiens 137-140 10887328-8 2000 This DNA-binding activity was inhibited by cyclosporin A, which indicated that NFATx nuclear translocation in CD4(+)CD8(+) thymocytes was regulated by calcineurin phosphatase. Cyclosporine 43-56 CD8a molecule Homo sapiens 116-119 9440547-7 1997 CONCLUSIONS: The results indicate that administration of cyclosporine and interferon-gamma after PBSC transplantation can induce autocytotoxic CD8+ T cells, even though it may not produce autologous graft-versus-host disease. Cyclosporine 57-69 CD8a molecule Homo sapiens 143-146 9973645-0 1998 Pure red cell aplasia associated to clonal CD8+ T-cell large granular lymphocytosis: dependence on cyclosporin A therapy. Cyclosporine 99-112 CD8a molecule Homo sapiens 43-46 9486927-0 1998 Red cell aplasia and megakaryocytic hypoplasia with elevated counts of CD8-positive lymphocytes after resection of a thymoma responding to cyclosporine. Cyclosporine 139-151 CD8a molecule Homo sapiens 71-74 9950598-10 1999 CONCLUSIONS: The in vitro effects of CsA translate into a reduction in T cells, a normalization of the CD4-CD8 ratio, a decrease in T-cell activation, and a reduction in T-cell cytokine expression, especially IL-2 and IFN-gamma. Cyclosporine 37-40 CD8a molecule Homo sapiens 107-110 9865295-0 1998 Enhanced efficacy of repeated anti-CD8 monoclonal antibody therapy by high-dose cyclosporine treatment. Cyclosporine 80-92 CD8a molecule Homo sapiens 35-38 9519776-5 1998 Vbeta7.1/CD8/CD3 triple immunofluorescence stainings appeared to be valuable for titrating the cyclosporin A dosage by monitoring the T-LGL cells during treatment. Cyclosporine 95-108 CD8a molecule Homo sapiens 9-12